Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen monograph

Executive Summary

FDA should "move up" anticipated implementation date so standards take effect before 2005, American Academy of Dermatology Association says in April 1 comments. "Proceedings of the UVA consensus conference, summarized in the AADA policy, represent a body of immediately accessible knowledge that should be tapped" and should "substantially shorten the amount of time needed" for FDA to draft a sunscreen monograph amendment, group says. Agency, which postponed Dec. 31, 2002 implementation date to create a comprehensive amendment addressing UVA protection, does not expect a new effective date prior to January 2005 (1"The Rose Sheet" Jan. 7, 2002, p. 3). AADA, Skin Cancer Foundation also urge FDA to remove monograph's SPF "30-plus" cap on labeling...
Advertisement

Related Content

Sunscreen Monograph Effective Date Extended To Address UVA Standards
Sunscreen Monograph Effective Date Extended To Address UVA Standards
Advertisement
UsernamePublicRestriction

Register

RS010190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel